Peter Curtin, M.D.

800-826-4673
Peter Curtin, M.D.
Hematologist-Oncologist
Clinical Expertise
  • Leukemia
Research Area
  • Acute Leukemia
  • Myelodysplastic Syndromes
Academic Appointments
  • Professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation
Clinical Teams
Hematology & Hematopoietic Cell Transplantation
Leukemia
“This man helped save my life ... he's amazing!” - Patient
Peter Curtin, M.D. gets rave reviews from his patients for his skills, his four decades experience and his compassionate care. Named a Top Doctor twice, he sees City of Hope as a perfect fit. “I want to be part of the team that provides both new and innovative therapies, and compassionate and comprehensive cancer care to the people of Southern California,” he said.
 
A Harvard graduate, Dr. Curtin earned his medical degree at SUNY Upstate Medical College in Syracuse, New York, and continued his training at North Carolina Memorial Hospital in Chapel Hill, North Carolina, and University of California San Francisco. Before joining City of Hope, he served 13 years as clinical director of the Blood & Marrow Transplantation Division at University of California San Diego.
 
Dr. Curtin remembers how his father, an orthopedic surgeon, “loved to be in the clinic and in the operating room, he loved teaching residents and fellows and, most of all, he loved interacting with patients and working to get them better ... I knew, very early on, that this was what I wanted to do with my life.”
 
Dr. Curtin focuses his research on developing new and better treatments for acute leukemia and myelodysplastic syndromes. “I wanted to be part of the quest to improve the treatment of these disorders and to increase the number of patients who were cured,” he explained. “While we have made significant progress, much work remains to be done.”

Location

Education & Experience

Board Certifications

  • 1985, American Board of Internal Medicine, Medical Oncology

  • 1984, American Board of Internal Medicine, Hematology

  • 1982, American Board of Internal Medicine

Degrees

  • 1979, M.D., S.U.N.Y-Upstate Medical College, Syracuse, NY

  • 1975, A.B., English Literature, Harvard University, Cambridge, MA

Fellowship

  • 1984-1987, Postdoctoral fellow, Y.W. Kan laboratory, Howard Hughes Medical Institute, University of California San Francisco, San Francisco, CA

  • 1982-1985, Hematology-Oncology, Cancer Research Institute and Department of Medicine, University of California San Francisco, San Francisco, CA

Residency

  • 1979-1982, Internal Medicine, North Carolina Memorial Hospital, Chapel Hill, NC

Professional Experience

  • 2020-present, Professor, Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

  • 2007-2020, Professor of Clinical Medicine, Clinical Director,
    Blood & Marrow Transplantation Division, Department of Medicine, University of California San Diego, La Jolla, CA

  • 2002-2007, Director, MDS Center of Excellence, Oregon Health & Science University, Portland, OR

  • 2000-2007, Associate Professor, Division of Hematology and Medical Oncology, Oregon Health & Science University, Department of Medicine, Portland, OR

  • 1998-2000, Assistant Professor, Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, OR

  • 1997-1998, Associate Director, Research, Cancer Genomics, Director of Laser Capture Microscopy and Tumor Sample Bank, Chiron Corporation, Emeryville, CA

  • 1996-1997, Associate Director, Clinical Development, Project Leader: Interleukin-2 in HIV Disease, Chiron Corporation, Emeryville, CA

  • 1996-1998, Assistant Clinical Professor, Department of Medicine, University of California San Francisco, San Francisco, CA

  • 1993-1996, Assistant Professor, Division of Hematology and Oncology, Department of Medicine and Program in Genetics, Tufts University School of Medicine, Boston, MA

  • 1989-1993, Acting Chief, Division of Molecular Hematology and Genetics, Department of Medicine, University of California San Francisco, San Francisco, CA

  • 1989-1993, Assistant Professor, Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA

  • 1987-1989, Clinical Instructor, Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA

Awards & Memberships

Awards

  • 2013, 2015, Hematology and Oncology, San Diego Magazine “Best Doctor”

  • 1987, Lita Annenberg Hazen Fellow

  • 1979, Alpha Omega Alpha, S.U.N.Y., Upstate Medical College

  • 1975, A.B. cum laude in English literature, Harvard University

Memberships

  • 1998-2007, Member, Oregon Cancer Center, Oregon Health & Science University, Portland, OR

  • 1998-2007, Member, Northwest Marrow Transplant Program, Oregon Health & Science University, Portland, OR

Publications

  • Aribi A, Salhotra A, Afkhami M, Munteanu A, Ali H, Aldoss I, Otoukesh S, Al Malki MM, Sandhu KS, Koller P, Arslan S, Stewart F, Artz A, Curtin P, Ball B, O'Hearn J, Spielberger R, Smith E, Budde E, Nakamura R, Stein A, Forman S, Marcucci G, Becker PS, Pullarkat V.WT1-mutated acute myeloid leukemia is sensitive to fludarabine-based chemotherapy and conditioning regimens. Leuk Lymphoma. 2023 Aug 3:1-11. doi: 10.1080/10428194.2023.2241096. Epub ahead of print. PMID: 37533373.
  • Yao JM, Otoukesh S, Kim H, Yang D, Mokhtari S, Samara Y, Blackmon A, Arslan S, Agrawal V, Pourhassan H, Amanam I, Ball B, Koller P, Salhotra A, Becker P, Curtin P, Artz A, Aldoss I, Ali H, Stewart F, Smith E, Stein A, Marcucci G, Forman SJ, Nakamura R, Al Malki MM. Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis. Transplant Cell Ther. 2023 Aug;29(8):515.e1-515.e7. doi: 10.1016/j.jtct.2023.05.008. Epub 2023 May 12. PMID: 37182736.
  • Shen G, Moua KTY, Perkins K, Johnson D, Li A, Curtin P, Gao W, McCune JS. Precision sirolimus dosing in children: The potential for model-informed dosing and novel drug monitoring. Front Pharmacol. 2023 Mar 20;14:1126981. doi: 10.3389/fphar.2023.1126981. PMID: 37021042; PMCID: PMC10069443.
  • Aldoss I, Afkhami M, Yang D, Gu Z, Mokhtari S, Shahani S, Pourhassan H, Agrawal V, Koller P, Arslan S, Tomasian V, Al Malki MM, Artz A, Salhotra A, Ali H, Aribi A, Sandhu KS, Ball B, Otoukesh S, Amanam I, Becker PS, Stewart FM, Curtin P, Smith E, Telatar M, Stein AS, Marcucci G, Forman SJ, Nakamura R, Pullarkat V. High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusions. Am J Hematol. 2023 Jun;98(6):848-856. doi: 10.1002/ajh.26908. Epub 2023 Mar 16. PMID: 36880203.
  • Agrawal V, Pourhassan H, Tsai NC, Ngo D, Koller P, Malki MMA, Salhotra A, Ali H, Aribi A, Sandhu KS, Arslan S, Ball B, Otoukesh S, Amanam I, Artz A, Singh D, Becker PS, Stewart FM, Smith EP, Curtin P, Stein AS, Marcucci G, Forman SJ, Nakamura R, Pullarkat V, Aldoss I. Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab. Transplant Cell Ther. 2023 May;29(5):314-320. doi: 10.1016/j.jtct.2023.01.017. Epub 2023 Jan 19. PMID: 36682470.
  • Agrawal V, Pourhassan H, Tsai NC, Ngo D, Koller P, Malki MMA, Salhotra A, Ali H, Aribi A, Sandhu KS, Arslan S, Ball B, Otoukesh S, Amanam I, Artz A, Singh D, Becker PS, Stewart FM, Smith EP, Curtin P, Stein AS, Marcucci G, Forman SJ, Nakamura R, Pullarkat V, Aldoss I. Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab. Transplant Cell Ther. 2023 May;29(5):314-320. doi: 10.1016/j.jtct.2023.01.017. Epub 2023 Jan 19. PMID: 36682470.
  • Aldoss I, Yang D, Tomasian V, Mokhtari S, Jackson R, Gu Z, Telatar M, Yew H, Al Malki MM, Salhotra A, Khaled S, Ali H, Aribi A, Sandhu KS, Mei M, Arslan S, Koller P, Artz A, Aoun P, Gu D, Snyder D, Stewart FM, Curtin P, Stein AS, Pillai R, Marcucci G, Forman SJ, Pullarkat V, Nakamura R, Afkhami M. Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL. Blood Adv. 2022 Sep 13;6(17):4936-4948. doi: 10.1182/bloodadvances.2022007597. PMID: 35816633; PMCID: PMC9631622.
  • Kansu E, Ward D, Sanchez AP, Cunard R, Hayran M, Huseyin B, Vaughan M, Ku G, Curtin P, Mulroney C, Costello C, Castro JE, Wieduwilt M, Corringham S, Ihasz-Davis A, Nelson C, Ball ED. Extracorporeal photopheresis for the treatment of chronic graft versus host disease. Hematology. 2022 Dec;27(1):785-794. doi: 10.1080/16078454.2022.2095884. PMID: 35802815.
  • Pourhassan H, Yang D, Afkhami M, Pillai R, Ball B, Al Malki M, Salhotra A, Ali H, Artz A, Curtin P, Armenian S, Stein A, Forman SJ, Marcucci G, Pullarkat V, Nakamura R, Aldoss I. High prevalence and inferior long-term outcomes for TP53 mutations in therapy-related acute lymphoblastic leukemia. Am J Hematol. 2022 May;97(5):E171-E173. doi: 10.1002/ajh.26490. Epub 2022 Feb 11. PMID: 35132678.
  • Pourhassan H, Yang D, Afkhami M, Pillai R, Ball B, Al Malki M, Salhotra A, Ali H, Artz A, Curtin P, Armenian S, Stein A, Forman SJ, Marcucci G, Pullarkat V, Nakamura R, Aldoss I. High prevalence and inferior long-term outcomes for TP53 mutations in therapy-related acute lymphoblastic leukemia. Am J Hematol. 2022 May;97(5):E171-E173. doi: 10.1002/ajh.26490. Epub 2022 Feb 11. PMID: 35132678.

Ratings & Reviews

Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with five stars being the highest.